S
Sherwyn Schwartz
Researcher at Novo Nordisk
Publications - 71
Citations - 10626
Sherwyn Schwartz is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Diabetes mellitus & Insulin. The author has an hindex of 42, co-authored 71 publications receiving 10365 citations. Previous affiliations of Sherwyn Schwartz include University of Connecticut Health Center.
Papers
More filters
Journal ArticleDOI
Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Controlled Trial
Miroslav Backonja,Ahmad Beydoun,Keith R. Edwards,Sherwyn Schwartz,Vivian Fonseca,Marykay Hes,L. LaMoreaux,Elizabeth A. Garofalo +7 more
TL;DR: Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.
Journal ArticleDOI
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman,John E. Gerich,John B. Buse,Andrew Lewin,Sherwyn Schwartz,Philip Raskin,Paula M Hale,Milan Zdravkovic,Lawrence Blonde +8 more
TL;DR: Liraglutide combined with metformin and a thiazolidinedione is a well-tolerated combination therapy for type 2 diabetes, providing significant improvements in glycemic control and C-peptide and homeostasis model assessment of β-cell function.
Journal ArticleDOI
Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.
Satish K. Garg,Howard Zisser,Sherwyn Schwartz,Timothy L. Bailey,Roy Kaplan,Samuel L. Ellis,Lois Jovanovic +6 more
TL;DR: It is demonstrated that availability of real-time, continuously measured glucose levels can significantly improve glycemic excursions by reducing exposure to hyperglycemia without increasing the risk of hypoglycemia, which may reduce long-term diabetes complications and their associated economic costs.
Journal ArticleDOI
Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin
TL;DR: In patients with type 2 diabetes, once-daily bedtime insulin glargine is as effective as once- or twice-daily NPH in improving and maintaining glycemic control and deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin.
Journal ArticleDOI
Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
J.W. Nawrocki,Stuart R. Weiss,Michael H. Davidson,Dennis L. Sprecher,Sherwyn Schwartz,Paul-J. Lupien,Peter B. Jones,H. E. Haber,Donald M. Black +8 more
TL;DR: Atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.